Skip to main content
    V

    Viridian Therapeutics Inc (VRDN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $29.80
    -1.07 (-3.47%)

    Market Cap: $3.51B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Viridian Therapeutics Inc (VRDN) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Viridian Therapeutics (VRDN) to earn -$3.51 per share in the fiscal year ending Dec 31, 2026, on revenue of $74.76M. Of 17 analysts, 17 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 5 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 17 ratings average 1.82, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy317.6%
    Buy1482.4%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    17

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 318.3%.

    Fiscal year ending Dec 31, 2026
    -$3.51
    EPS consensus, revenue $74.76M
    Fiscal year ending Dec 31, 2027
    -$2.13
    EPS consensus, revenue $312.69M
    Next report
    Feb 24, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$3.51-$3.98 to -$2.8113$74.76M$55.91M to $97.48M13
    Dec 31, 2027-$2.13-$3.94 to -$1.3613$312.69M$134.00M to $476.91M14

    Quarterly Estimates

    The EPS consensus falls from -$0.72 for the quarter ending Dec 31, 2026 to -$0.75 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.72-$0.83 to -$0.6116$50.04M$30.29M to $74.87M16
    Mar 31, 2027-$0.75-$0.95 to -$0.534$67.96M$53.00M to $82.81M4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 13 upward and 2 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202651
    Fiscal year ending Dec 31, 202771
    Quarter ending Mar 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.95.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$3.51-$3.92-$3.93-$3.95-$3.95N/A
    Fiscal year ending Dec 31, 2027-$2.13-$2.71-$2.75-$2.77-$2.77N/A
    Quarter ending Mar 31, 2027-$0.75-$0.88-$0.89-$0.89-$0.89N/A

    Frequently Asked Questions About VRDN

    What is the VRDN stock forecast?

    Consensus analyst estimates put Viridian Therapeutics's EPS at -$3.51 for the fiscal year ending Dec 31, 2026, on revenue of $74.76M. The consensus rating from 17 analysts is Buy.

    How do analysts rate VRDN stock?

    Of 17 analysts covering Viridian Therapeutics, 3 rate it Strong Buy, 14 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from VRDN next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.51, with estimates from -$3.98 to -$2.81 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.13, with estimates from -$3.94 to -$1.36 from 13 analysts.

    What revenue do analysts expect from Viridian Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $74.76M, with estimates from $55.91M to $97.48M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $312.69M, with estimates from $134.00M to $476.91M.

    How many analysts cover VRDN?

    17 analysts rate Viridian Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.